PGx Patients Facing Resistance from Providers Due to an Educational Gap
Discover why PGx patients facing resistance and the importance of bridging the educational gap in precision medicine for enhanced patient care.
Proper Chain of Custody for Genetic Testing Results to Avoid Conflict of Interest
Ensure the integrity of genetic tests with proper chain of custody for genetic testing results, safeguarding data and maintaining trust.
Predict High Sensitivity to Warfarin Through CYP2C9
Discover how CYP2C9 genetic variations impact warfarin sensitivity and can guide personalized anticoagulant therapy for better patient outcomes.
The Need for a Standardized Approach When Interpreting PGx Results
Explore the importance of a standardized approach in interpreting PGx results for effective personalized medicine guidance.
What is the Significance of Non-Metabolizing Genes and Why they Should be PGx Tested
Understand the crucial role of non-metabolizing genes and why they should be PGx tested and payor covered.
Preemptive Genetic Testing for TPMT and NUDT15
Uncover how preemptive genetic testing for TPMT and NUDT15 can guide safer drug use and individualized patient care.
What Diagnostic Innovators Need to Know About the Challenges of PCR testing From a MolDX Perspective
Explore the intricacies of PCR testing and how MolDX is shaping the future of precision medicine and molecular diagnostics.
How to Launch a Successful PGx Consulting Business in 2024
Elevate your PGx Consultant Business strategy with targeted insights for personalized medicine and pharmacogenomics. Boost patient engagement today.
Understanding DPD Deficiency: Causes & Effects
Uncover the impact of DPD deficiency on chemotherapy sensitivity and the importance of pharmacogenomics in personalized cancer treatment.
FOR IMMEDIATE RELEASE – American Pharmacogenomics Association Issues Statement on Final FDA Rule for Laboratory Developed Tests (LDTs)
The American Pharmacogenomics Association (APGxA) today issued a statement on the Food and Drug Administration’s (FDA) final rule regarding the regulation of laboratory-developed tests (LDTs).
End of content
End of content